Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2026-02-25 @ 10:05 PM
Study NCT ID:
NCT02036502
Status:
TERMINATED
Last Update Posted:
2021-04-08
First Post:
2014-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-02-14
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-03-19
Completion Date Type:
ACTUAL
First Submit Date:
2014-01-13
First Submit QC Date:
None
Study First Post Date:
2014-01-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-03-02
Results First Submit QC Date:
None
Results First Post Date:
2021-04-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-12
Last Update Post Date:
2021-04-08
Last Update Post Date Type:
ACTUAL